Barrington analyst Michael Petusky keeps an Outperform rating on Opko Health with a $7 price target following the company's "mixed" Q3 results. Revenues were light, but good expense management drove a slight earnings beat, Petusky tells investors in a post-earnings research note. The Novitas decision to draft non-coverage guidance for Opko's diagnostic for aggressive prostate cancer, 4Kscore, may now be providing a slight headwind to the company's results, the analyst contends. Nonetheless, he believes the stock's risk/reward continues to favor investment.